Enpatoran Phase 3 Trial Kickoff for Lupus Skin Manifestations
Key Questions
What is the ELOWEN Phase 3 trial for enpatoran?
Merck KGaA has dosed the first patient in the ELOWEN Phase 3 trial of enpatoran, a TLR7/8 inhibitor targeting skin manifestations of lupus. The study is led by Prof Eric Morand of Monash University and is currently recruiting participants.
What do the Phase 2 data show for enpatoran in lupus?
Extended Phase 2 results at 48 weeks demonstrate sustained efficacy and safety, with CLASI-A score reductions of 64-72%. These findings support continued development for lupus skin disease.
Has enpatoran received FDA breakthrough therapy designation?
Yes, the FDA has granted breakthrough status to enpatoran for the treatment of lupus. Merck KGaA announced the designation, highlighting its potential to address unmet medical needs.
Merck KGaA first patient dosed in ELOWEN Phase 3 led by Prof Eric Morand (Monash), recruiting; TLR7/8 inhibitor targets skin. Extended Phase 2 data (48 weeks) shows sustained efficacy and safety, with CLASI-A drops 64-72%. Ianatumumab also shows durable response after treatment cessation in Phase 2, relevant to immune reset discussions.